A Phase III Trial of Treatment of Advanced-Stage Anaplastic Large Cell Lymphoma (ALCL) With Standard APO (Doxorubicin, Prednisone, Vincristine) Versus Consolidation With a Regimen Including Vinblastine
A Phase III Trial of Treatment of Advanced-Stage Anaplastic Large Cell Lymphoma (ALCL) With Standard APO (Doxorubicin, Prednisone, Vincristine) Versus Consolidation With a Regimen Including Vinblastine
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. It is not yet known if combination chemotherapy with vinblastine is more effective than combination chemotherapy with vincristine in treating advanced anaplastic large cell lymphoma.
PURPOSE: Randomized phase III trial to compare the effectiveness of two combination chemotherapy regimens with either vinblastine or vincristine in treating patients who have newly diagnosed advanced anaplastic large cell lymphoma.
OBJECTIVES:
OUTLINE: This is a randomized, multicenter study.
Patients are randomized at enrollment to receive either Standard APO regimen or a consolidation regimen including vinblastine (VBL).
Patients undergo restaging after Induction such that consolidation therapy is started on day 43. All patients with complete response (CR), complete response unconfirmed (CRu) or partial response (PR) proceed to Consolidation based on CT or MRI scans at the end of induction (week 6). All other patients will be removed from protocol therapy and will be followed until they meet the criteria for off study. Follow-up data will be required unless consent is withdrawn.
Standard APO (Arm I): Patients receive course-specific regimens without vinblastine.
Consolidation with vinblastine (Arm II): Patients receive course-specific regimens including vinblastine.
In both arms and all courses, treatment repeats every 21 days for up to 15 courses in the absence of disease progression or unacceptable toxicity.
Patients are followed monthly for 1 year, every 3 months for 1 year, every 6 months for 1 year, and then annually thereafter.
PROJECTED ACCRUAL: A total of 200-250 patients (100-125 per treatment arm) will be accrued for this study within 5 years.
DISEASE CHARACTERISTICS:
Newly diagnosed advanced anaplastic large cell lymphoma
No B-cell large cell lymphoma
No disease limited to the skin (regardless of how wide-spread)
PATIENT CHARACTERISTICS:
Age
Performance status
Life expectancy
Hematopoietic
Hepatic
Renal
Cardiovascular
Other
PRIOR CONCURRENT THERAPY:
Biologic therapy
Chemotherapy
Endocrine therapy
Radiotherapy
Surgery
Birmingham, Alabama 35294, United States
Little Rock, Arkansas 72205, United States
Loma Linda, California 92354, United States
Farmington, Connecticut 06360-2875, United States
Miami, Florida 33136, United States
Orlando, Florida 32803-1273, United States
Savannah, Georgia 31403-3089, United States
Boise, Idaho 83712-6297, United States
Indianapolis, Indiana 46202-5289, United States
Lexington, Kentucky 40536-0093, United States
Boston, Massachusetts 02111, United States
Boston, Massachusetts 02115, United States
Springfield, Massachusetts 01199-0001, United States
Ann Arbor, Michigan 48109-0286, United States
Grosse Pointe Woods, Michigan 48236, United States
Minneapolis, Minnesota 55404, United States
Columbia, Missouri 65203, United States
St Louis, Missouri 63110, United States
Omaha, Nebraska 68198-6805, United States
Lebanon, New Hampshire 03756-0002, United States
New Brunswick, New Jersey 08903, United States
New York, New York 10032, United States
Rochester, New York 14642, United States
The Bronx, New York 10461, United States
Charlotte, North Carolina 28232-2861, United States
Charlotte, North Carolina 28233-3549, United States
Greenville, North Carolina 27835-6028, United States
Winston-Salem, North Carolina 27157-1096, United States
Portland, Oregon 97227, United States
Hershey, Pennsylvania 17033-0850, United States
Sioux Falls, South Dakota 57117-5039, United States
Amarillo, Texas 79106, United States
Dallas, Texas 75390, United States
Burlington, Vermont 05401, United States
Roanoke, Virginia 24014, United States
Spokane, Washington 99220-2555, United States
Charleston, West Virginia 25302, United States
Milwaukee, Wisconsin 53226, United States
Westmead, New South Wales 2145, Australia
St. John's, Newfoundland and Labrador A1B 3V6, Canada